Anti-Amyloid Antibodies for Alzheimer’s Disease: Efficacy and Safety

<p>This <strong>umbrella review</strong> evaluates the clinical efficacy and safety of two recently approved <strong>anti-amyloid antibodies</strong>, <strong>lecanemab</strong> and <strong>donanemab</strong>, for treating early-stage <strong>Alzheimer’s disease</strong>. By synthesizing data from eleven high-quality systematic reviews and meta-analyses, the authors conclude that these drugs successfully reduce <strong>brain amyloid burden</strong> and provide a statistically significant slowing of <strong>cognitive decline</strong>. However, the text highlights a critical concern: the observed cognitive benefits often fall below established <strong>clinically meaningful thresholds</strong>, suggesting that patients might not perceive a significant improvement in daily life. Furthermore, both treatments are associated with an increased risk of <strong>amyloid-related imaging abnormalities (ARIA)</strong>, such as brain edema and hemorrhage, particularly in <strong>ApoEε4 gene carriers</strong>. Consequently, the source emphasizes that prescribing these therapies requires rigorous <strong>patient selection</strong>, careful monitoring through regular MRIs, and transparent communication regarding the modest expected outcomes. Ultimately, while these antibodies represent a significant <strong>pharmacological shift</strong> in dementia care, their benefits must be carefully weighed against potential safety risks and high financial costs.</p>